CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 105,596	$ 298,172
Short-term marketable securities	61,855	29,312
Receivables from collaborative arrangements	15,796	16,785
Prepaid clinical and development services	979	1,513
Other prepaid and current assets	7,777	7,682
Total current assets	192,003	353,464
Property and equipment, net	9,553	11,875
Operating lease assets	38,453	40,126
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	11,585	6,899
Total assets	446,630	607,400
Current liabilities:
Accounts payable	1,569	1,554
Accrued personnel-related expenses	5,371	10,314
Accrued clinical and development expenses	4,006	4,932
Accrued general and administrative expenses	2,874	4,020
Operating lease liabilities	9,160	6,753
Deferred revenue	24	24
Other accrued liabilities	1,542	1,118
Total current liabilities	24,546	28,715
Long-term operating lease liabilities	42,521	45,407
Future royalty payment contingency	26,556	25,438
Long-term deferred revenue	181	192
Unrecognized tax benefits	64,987	64,191
Other long-term liabilities	7,678	1,657
Commitments and contingencies
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 53,694 and 65,227 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	1	1
Additional paid-in capital	1,172,090	1,295,725
Accumulated other comprehensive loss	(286)	(15)
Accumulated deficit	(891,644)	(853,911)
Total shareholders' equity	280,161	441,800
Total liabilities and shareholders' equity	$ 446,630	$ 607,400